Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Avosentan

Known as: 2-Pyridinesulfonamide, N-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl-, 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Numerous pre‐clinical studies have implicated endothelin‐1 in the pathogenesis of diabetic and non‐diabetic chronic kidney… Expand
2012
2012
Diabetic nephropathy remains the most common cause of ESRD, accounting for more than 40% of patients treated with dialysis. The… Expand
Review
2012
Review
2012
Diabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease in western countries. This implies that… Expand
Highly Cited
2010
Highly Cited
2010
In the short term, the endothelin antagonist avosentan reduces proteinuria, but whether this translates to protection from… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2010
2010
Individuals with chronic kidney disease (CKD) are more likely to die of cardiovascular causes than progress to end-stage renal… Expand
Highly Cited
2009
Highly Cited
2009
Despite the first-line use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), there is… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 5
Highly Cited
2009
Highly Cited
2009
In the present study, we evaluated the effect of simultaneously blocking angiotensin II synthesis and endothelin (ET)-1 activity… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2009
Highly Cited
2009
Aims/hypothesisThere is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2009
2009
The endothelin receptor antagonist avosentan may cause fluid overload at doses of 25 and 50 mg, but the actual mechanisms of this… Expand
Review
2006
Review
2006
Since its initial characterization in 1988, over 18,236 papers, including 2,485 reviews, have been published in the endothelin… Expand
  • figure 1
  • figure 1
  • figure 1